Neuralstem (CUR) Price Target Cut to $1.91 by Analysts at S&P Equity Research
Neuralstem (NASDAQ:CUR) had its price objective dropped by equities researchers at S&P Equity Research from $2.26 to $1.91 in a research report issued on Thursday.
Shares of Neuralstem (NASDAQ:CUR) traded up $0.09 on Thursday, hitting $1.91. The stock had a trading volume of 504,100 shares, compared to its average volume of 328,714. The company has a market cap of $33.98, a P/E ratio of -1.15 and a beta of 1.60. Neuralstem has a 12-month low of $0.88 and a 12-month high of $6.60.
Large investors have recently added to or reduced their stakes in the stock. National Asset Management Inc. grew its stake in Neuralstem by 9.2% in the second quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock worth $134,000 after purchasing an additional 1,937 shares during the period. Blair William & Co. IL grew its stake in Neuralstem by 171.0% in the second quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock worth $506,000 after purchasing an additional 55,115 shares during the period. Alethea Capital Management LLC purchased a new stake in Neuralstem in the first quarter worth $868,000. Vanguard Group Inc. boosted its holdings in Neuralstem by 1.1% in the second quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock worth $2,000,000 after acquiring an additional 3,853 shares in the last quarter. Finally, Sabby Management LLC bought a new stake in Neuralstem in the second quarter worth $1,893,000. Institutional investors own 7.05% of the company’s stock.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.